
Introduction:Systemic lupus erythematosus (SLE) is a multisystem disease with a heterogenous pathophysiological mechanisms that lead to a variety of clinical, immunological, and neuropsychiatric manifestations. Areas covered:In this review, we will summarize the current understanding of molecular pathways involved in SLE and neuropsychiatric manifestations, focusing on genetic and epigenetic mechanisms and the implications of these findings in differences observed in treatment response. Expert opinion:Great progress has been made in understanding the heterogeneity in SLE, which may help direct therapy. However, neuropsychiatric manifestations still are a challenge in clinical practice, and future studies are needed to identify relevant diagnostic and prognostic biomarkers.
Introduction:Colorectal cancer (CRC) is the fourth most common cancer and second leading cause of cancer-related death in the United States. The implementation of CRC screening has decreased CRC incidence in adults older than 65 years. However, among young adults who experience more aggressive disease progression, CRC incidence has been increasing for decades. Immunotherapy represents a collection of innovative and promising approaches with greater efficacy and safety. In this review, we discuss modalities and selected targets of immunotherapies for CRCs that are guided by precision medicine. Areas covered:The following review focuses on immunological approaches for CRCs, including therapeutic monoclonal antibodies, immune checkpoint blockade, cancer vaccines, and adoptive cell therapies. Expert opinion:Metastatic and refractory CRCs are significant causes of cancer-related mortality and remain difficult to treat with current standard therapies. Following multiple FDA approvals for hematologic malignancies, research into solid tumor immunotherapies has substantially increased. Several chimeric antigen receptor (CAR)-expressing T cell therapies are showing promise in CRC. Moreover, immune checkpoint blocking antibodies are transforming care for a subset of CRC patients. With advances in our understanding of oncogenic mechanisms and development of novel treatment approaches, personalized immunotherapies are poised to dramatically change the landscape of CRC treatment.
Introduction Precision medicine customizes prevention, diagnosis, and treatment based on individual characteristics. Despite advancements, significant challenges remain in the widespread implementation of precision medicine across low- to middle-income countries (LMICs) such as Colombia. This review aims to identify and propose possible solutions to help close this gap. Areas covered Implementing precision medicine in LMICs requires addressing key barriers such as limited technology, inadequate healthcare training, ethical considerations, insufficient insurance coverage, public attitudes, high costs, and lack of political support. Expert opinion Precision medicine has the potential to revolutionize patient care and healthcare practices. By addressing these challenges and prioritizing strategic development areas, LMICs can fully embrace it, leading to significant improvements in healthcare outcomes for their diverse populations.
Introduction The drug development process traditionally includes rigorous pre-clinical testing in laboratories and animal models to assess the safety, efficacy, pharmacokinetics, and toxicology of potential drug candidates before progressing to human clinical trials. Developing AI, machine ML algorithms, and PM approaches will facilitate identifying potential drug targets, predicting therapeutic outcomes, and optimizing the selection of lead compounds.